Value Line, Inc. Announces a Quarterly Cash Dividend of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
157
Value Line, Inc. Announces a Quarterly Cash Dividend of $0.18 Per Common Share

NEW YORK, July 21, 2017 (GLOBE NEWSWIRE) -- Value Line, Inc., (NASDAQ: VALU ) announced that its Board of Directors declared on July 21, 2017 a quarterly cash dividend of $0.18 per common share, payable on August 11, 2017, to stockholders of record on July 31, 2017.  The Company has 9,709,312 shares of common stock outstanding as of July 21, 2017.

Value Line, Inc. is a leading New York based provider of investment research. The Value Line Investment Survey is one of the most widely used sources of independent equity investment research.  Value Line also publishes a range of proprietary investment research in both print and digital formats including research in the areas of Mutual Funds, Options and Convertible securities.  Value Line’s acclaimed research also enables the Company to provide specialized products such as Value Line Select, Value Line Special Situations, Value Line Select: Dividend Income & Growth, and copyright data , distributed under copyright agreements for fees, including certain proprietary ranking system information and other proprietary information used in third party products.  Investment Management services are provided through its substantial non-controlling and non-voting interests in EULAV Asset Management, the investment advisor to The Value Line Family of Mutual Funds. Value Line’s products are available to individual investors by mail, at www.valueline.com or through 1-800-VALUELINE or 1-800-535-9648, while institutional-level services for professional investors, advisers, corporate, academic, municipal and legal libraries are offered at www.ValueLinePro.com , www.ValueLineLibrary.com and at 1-800-531-1425. 

Cautionary Statement Regarding Forward-Looking Information

This report contains statements that are predictive in nature, depend upon or refer to future events or conditions (including certain projections and business trends) accompanied by such phrases as “believe”, “estimate”, “expect”, “anticipate”, “will”, “intend” and other similar or negative expressions, that are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995, as amended.  Actual results for Value Line, Inc. (“Value Line” or “the Company”) may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to the following:

  • maintaining revenue from subscriptions for the Company’s digital and print published products;
  • changes in market and economic conditions, including global financial issues;
  • protection of intellectual property rights;
  • dependence on non-voting revenues and non-voting profits interests in EULAV Asset Management, a Delaware statutory trust (“EAM” or “EAM Trust”), which serves as the investment advisor to the Value Line Funds and engages in related distribution, marketing and administrative services;
  • fluctuations in EAM’s assets under management due to broadly based changes in the values of equity and debt securities, redemptions by investors and other factors, and the effect these changes may have on the valuation of EAM’s intangible assets;
  • dependence on key personnel;
  • competition in the fields of publishing, copyright data and investment management;
  • the impact of government regulation on the Company’s and EAM’s businesses;
  • availability of free or low cost investment data through discount brokers or generally over the internet;
  • terrorist attacks, cyber attacks and natural disasters;
  • other risks and uncertainties, including but not limited to the risks described in Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended April 30, 2016; and in Part II, Item 1A of the Quarterly Report on Form 10-Q for the period ended January 31, 2017; and
  • other risks and uncertainties arising from time to time.

These factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors which may involve external factors over which we may have no control or changes in our plans, strategies, objectives, expectations or intentions, which may happen at any time at our discretion, could also have material adverse effects on future results. Except as otherwise required to be disclosed in periodic reports required to be filed by public companies with the SEC pursuant to the SEC's rules, we have no duty to update these statements, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks and uncertainties, current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking information contained herein.

Contact: Howard A. Brecher                                                                                                             Value Line, Inc. (212) 907-1500                                                                                    www.valueline.com www.ValueLinePro.com , www.ValueLineLibrary.com Facebook | Google + | LinkedIn | Twitter Complimentary Value Line® Reports on Dow 30 Stocks

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 5

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading

Top 5 Most Recently Viewed Articles

BioCryst Pharmaceuticals Reports Positive Outcomes for ORLADEYO

Updated Category News Views 62

BioCryst Pharmaceuticals Highlights ORLADEYO's Impact BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has unveiled a compelling study that underscores how ORLADEYO (berotralstat) significantly lowers healthcare resource utilization (HRU) for patients battling hereditary angioedema (HAE). This innovative oral treatment has garnered attention due to its remarkable findings,...

Continue Reading
Man Group PLC Discloses Interest in Spectris plc Shares

Updated Category News Views 174

Understanding Man Group PLC's Position Disclosure Man Group PLC is making headlines as it officially discloses its holdings in Spectris plc. This disclosure is known as FORM 8.3 and is a crucial document under Rule 8.3 of the Takeover Code. It indicates the shareholding interests of Man Group in Spectris, representing a significant percentage of the company's relevant...

Continue Reading
Centessa Pharmaceuticals Seeks $225 Million Through Public Offering

Updated Category News Views 91

Centessa Pharmaceuticals Launches Major $225 Million Offering Centessa Pharmaceuticals plc (NASDAQ: CNTA), an innovative clinical-stage pharmaceutical company, has announced an ambitious public offering with the goal of raising around $225 million. This offering features 15,254,237 American Depositary Shares (ADSs), each representing one ordinary share, priced at $14.75...

Continue Reading
Unveiling Software Giants: Microsoft and Its Rivals in 2024

Updated Category News Views 350

Understanding the Competitive Landscape of Software Giants In the dynamic world of software, staying informed about leading companies is vital for investors and analysts alike. This article focuses on Microsoft (NASDAQ: MSFT) and its primary competitors, aiming to deliver a thorough analysis of financial statistics, market standings, and opportunities for growth within...

Continue Reading
Harris Leads Trump by 3 Points in Key Election Polls

Updated Category News Views 105

Election Polls Show Harris's Slim Lead Over Trump In the battleground of the upcoming U.S. presidential election, Democratic Vice President Kamala Harris has established a slender lead over Republican contender Donald Trump, according to the latest polling data. Recent surveys indicate that Harris is ahead by a margin of 3 points, with her support reaching 45% compared to...

Continue Reading